Avadel Pharmaceuticals PLC

NASDAQ:AVDLUnited States

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Contact Information

Headquarters

Block 10-1 Blanchardstown Corporate Park BallycoolinDUBLIN, Ireland 15

Phone

---

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Geoffrey Glass

Chief Executive Officer, Director

Gregory Divis

Chief Financial Officer

Thomas McHugh

Chief Commercial Officer

Richard Kim

Independent Director

Naseem Amin